Evidence map›Paper›PMID 34200144›Full record

ArticleMolecules (Basel, Switzerland)2021

Quality by Design for Development, Optimization and Characterization of Brucine Ethosomal Gel for Skin Cancer Delivery.

Tamer A Ismail, Tamer M Shehata, Dalia I Mohamed, Heba S Elsewedy, Wafaa E Soliman

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Nanotechnology as a Promising Method in the Treatment of Skin Cancer.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Tamer A IsmailDepartment of Clinical Laboratory Sciences, Turabah University College, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.ORCID 0000-0001-5445-5877
Tamer M ShehataDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Hofuf 36362, Saudi Arabia.ORCID 0000-0002-8051-1614
Dalia I MohamedDepartment of Biochemistry, Zagazig Branch, Agriculture Research Center, Animal Health Research Institute, Zagazig 44519, Egypt.
Heba S ElsewedyDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Hofuf 36362, Saudi Arabia.ORCID 0000-0002-3221-9168
Wafaa E SolimanDepartment of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Hofuf 36362, Saudi Arabia.ORCID 0000-0001-6549-0926
King Faisal University · SATaif University · SAZagazig University · EG

Funding

Taif University Researchers Supporting, Taif University, Taif, Saudi Arabia (TURSP-2020/134)
6 · The paper itself

Abstract

Natural products have been extensively used for treating a wide variety of disorders. In recent times, Brucine (BRU) as one of the natural medications extracted from seeds of nux vomica, was investigated for its anticancer activity. As far as we know, this is the first study on BRU anticancer activity against skin cancer. Thus, the rational of this work was implemented to develop, optimize and characterize the anticancer activity of BRU loaded ethosomal gel. Basically, thin film hydration method was used to formulate BRU ethosomal preparations, by means of Central composite design (CCD), which were operated to construct (3

Indexed as

Administration, CutaneousAnimalsEthanolGelsMalePhospholipidsRatsRats, WistarSkinSkin AbsorptionSkin NeoplasmsStrychninebrucineEthanolGelsPhospholipidsStrychninebrucineethosomeoptimizationskintransdermal drug delivery

Identifiers

PMID34200144
PMCPMC8201187
OpenAlexW3172153894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.